Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Insights From Genomic Approaches to Oncology Discovery

April 12th 2012

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Optical Biomarkers Distinguish Risk Levels in Barrett's Esophagus

April 12th 2012

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Dr. Spector Discusses the Systemic Nature of Cancer

April 10th 2012

Dr. Neil Spector, from Duke Cancer Institute, Discusses the Systemic Nature of Cancer

Personalized Medicine: A Promising Future in Oncology Practice

April 10th 2012

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

Dual Inhibitors Explored in Triple-Negative Tumors

April 9th 2012

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

Targeted Therapies in Breast Cancer Offer Increasing Hope and Complexity

April 2nd 2012

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.

Dr. Perou on Next Generation Sequencing Technology

March 30th 2012

Dr. Charles Perou, from the UNC Lineberger Comprehensive Cancer Center, on Next Generation Sequencing Technology

Dr. Zelenetz Discusses DLBCL Targeted Therapies

March 29th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Ellis Describes Breast Cancer Heterogeneity

March 27th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

Examining the HER2 Testing Puzzle: Fresh Research Explores Nagging Questions

March 27th 2012

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Improved Survival in Women With Invasive Epithelial Ovarian Cancer and Germline BRCA Gene Mutations

March 26th 2012

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Spector Discusses the Complexities of Cancer

March 26th 2012

Dr. Neil Spector, from the Duke Cancer Institute, Discusses the Complexities of Cancer

Dr. Dunleavy Discusses ABC DLBCL Research

March 23rd 2012

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research

MET Receptor Pathway: A Bounty of Targeted Options Explored

March 23rd 2012

The MET signaling network has emerged as an important target for cancer therapy, with a particularly significant role in controlling the cancer hallmarks of metastasis and angiogenesis.

Dr. Chang on Combining HER2 Targeted Therapies

March 22nd 2012

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

Massachusetts General Hospital Cancer Center: At the Forefront of Personalized Care

March 22nd 2012

The Massachusetts General Hospital (MGH) Cancer Center comprises 23 fully integrated, multidisciplinary clinical programs, as well as an extensive array of support and educational services.

Five Questions for Jill M. Siegfried, PhD

March 22nd 2012

Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.

Analyzing Disease Flares: Impact of Discontinuing Targeted Therapy Unclear

March 21st 2012

It is always difficult to distinguish what may legitimately be considered disease flare from the more likely scenario of the events simply representing the natural history of the malignancy.

Drug Interactions Significantly Reduce Targeted Therapy Efficacy

March 16th 2012

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.

Dr. Perez-Soler on the Future of Lung Cancer Therapies

March 13th 2012

Dr. Roman Perez-Soler, from Albert Einstein College of Medicine, on the Future of Lung Cancer Therapies